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Abstract
Background: Despite substantial improvements in surgical and anesthesiological practices leading to decreased
mortality of less than 5 % at high-volume centers, pancreatic surgery is still associated with high morbidity rates of
up to 50 %. Attention is increasingly directed toward the optimization of perioperative management to reduce
complications and enhance postoperative recovery. Currently, two different strategies for postoperative pain
management after pancreatoduodenectomy are being routinely used: patient-controlled intravenous analgesia
and thoracic epidural analgesia. Evidence is lacking to assess which strategy entails fewer postoperative complications.
Methods/design: The PAKMAN trial is designed as an adaptive, pragmatic, randomized, controlled, multicenter,
open-label, superiority trial with two parallel study groups. A total of 370 patients scheduled for elective
pancreatoduodenectomy will be randomized after giving written informed consent, and 278 patients are needed
for analysis. Patients with chronic pancreatitis, severe chronic obstructive pulmonary disease (COPD), American
Society of Anesthesiologists (ASA) physical status classification ≥ IV, or chronic pain syndrome will be excluded.
The group A intervention includes intraoperative general anesthesia and postoperative patient-controlled intravenous
analgesia; the group B intervention comprises combined intraoperative general anesthesia and epidural analgesia with
postoperative epidural analgesia. The primary endpoint of this trial is a composite of the gastrointestinal complications
(delayed gastric emptying, pancreatic fistula, biliary leak, gastrointestinal bleeding, and postoperative ileus) up to
postoperative day 30. The aim is to investigate whether the frequency of gastrointestinal complications following
pancreatoduodenectomy can be reduced by 15 % using postoperative, patient-controlled intravenous analgesia
compared with epidural analgesia.
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Discussion: Several previous studies investigating the two different strategies for postoperative pain management
have mainly focused on their effectiveness in pain control. However, the PAKMAN trial is the first to compare
them with regard to their impact on the surgical endpoint “postoperative gastrointestinal complications” after
pancreatoduodenectomy.
Trial registration: German Clinical Trials Register, DRKS00007784
Keywords: Epidural analgesia, Patient-controlled intravenous analgesia, Pancreatoduodenectomy, Postoperative
pain management, Postoperative complication, Randomized controlled trial
Background
Owing to significant improvements in surgical and
anesthesiological practices, mortality in pancreatic sur-
gery has been reduced to less than 5 % at high-volume
centers. However, even specialized centers with highly
standardized surgical techniques still report morbidity
rates of up to 50 %, mainly due to gastrointestinal com-
plications [1]. As one of the most important complica-
tions, postoperative pancreatic fistula can lead to further
adverse effects such as erosion bleeding, intra-abdominal
abscess, or sepsis [2]. With regard to patient outcome
after pancreatoduodenectomy, the recently published
RecoPanc trial (DRKS00000767) compared pancreato-
gastrostomy with pancreatojejunostomy and showed no
significant difference in the rate of pancreatic fistula [3].
Along with the constant refinement of surgical tech-
nique during the past two decades, increasing attention
is now being directed toward the optimization of peri-
operative management to reduce complications and en-
hance postoperative recovery.
The most common strategies for effective periopera-
tive pain management in major abdominal surgery are
patient-controlled intravenous opioid analgesia (IV-
PCA) and epidural analgesia (EDA) [4]. A retrospective
study of perioperative pain management strategies in
pancreatic surgery published in 2008 [5] found that
EDA with additional intravenous analgesia was associ-
ated with a lower occurrence of postoperative gastro-
intestinal and infectious complications than EDA
alone. The aim of the trial described here is to verify
this association in a multicenter RCT.
EDA is usually achieved by combined injection of
local anesthetics and opioids into the epidural space.
This inhibits neural transmission and induces anal-
gesia. Additionally, the action of the sympathetic ner-
vous system is lessened, and vasodilation is provoked.
Major abdominal surgery frequently entails large vol-
ume shifts and significant blood losses. Some evidence
exists that EDA provokes hemodynamic instability in
this setting [6, 7]. Typically, vasopressors and large
amounts of fluids are administered to counteract un-
desirable hypotension. These interventions may affect
the healing of gastrointestinal anastomoses in a negative
manner and possibly increase the incidence of complica-
tions such as anastomotic insufficiency. A prospective
study identified hypotension during abdominal surgery as
a significant risk factor for postoperative complications
[8]. In a randomized controlled trial (RCT) of patients
undergoing pancreatoduodenectomy, greater intraopera-
tive fluid administration resulted in more pancreatic anas-
tomotic complications [9]. Pratt et al. showed a significant
decrease of 15 % in gastrointestinal complications for
patients undergoing pancreatoduodenectomy with post-
operative intravenous analgesia versus thoracic EDA [5].
Although thoracic EDA is effective in pain control, its
possible adverse effects on postoperative recovery of pa-
tients after pancreatoduodenectomy may represent a major
disadvantage. Perioperative pain management with IV-PCA
may reduce the individual risk of postoperative complica-
tions. The PAKMAN trial will establish whether IV-PCA is
able to improve patients’ surgical outcomes compared with
EDA, thereby potentially changing medical practice.
Methods/design
Trial rationale
The aim of this pragmatic (effectiveness) trial is the com-
parison of two different perioperative pain-management
strategies in pancreatic surgery with regard to gastrointes-
tinal complications up to postoperative day (POD) 30. We
postulate that the healing of anastomoses may be compro-
mised by the increased intraoperative administration of
vasopressors and intravenous fluids due to the vasodila-
tory effect of EDA. The primary objective of the trial is to
investigate whether the frequency of the composite pri-
mary endpoint of gastrointestinal complications (delayed
gastric emptying, pancreatic fistula, biliary leak, gastro-
intestinal bleeding, or postoperative ileus) following
pancreatoduodenectomy could be reduced by 15 % by
postoperative IV-PCA compared with thoracic EDA.
Trial design
PAKMAN is an investigator-initiated, adaptive, prag-
matic, randomized, controlled, multicenter, open-label,
superiority trial with two parallel study groups.
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Eligibility
Eligibility criteria for participating trial centers
Established trial infrastructures from previously con-
ducted multicenter trials (DISPACT and RecoPanc) will
be used for the PAKMAN trial [3, 10]. Eight German
(Dresden, Freiburg, Giessen, Heidelberg, Lübeck, Munich
LMU, Stuttgart, and Tübingen), and three other European
(Liverpool, Ljubljana, and Verona) high-volume centers
with broad expertise in pancreatic surgery will be included.
Inclusion criteria
All patients scheduled for elective pancreatoduodenect-
omy at one of the participating centers will be screened
consecutively for eligibility and will be informed about
the PAKMAN trial during a pretreatment visit or on
the day of admission to the hospital. All subjects must
be able to understand the nature and potential individ-
ual consequences of the clinical trial, and only adult pa-
tients (≥ 18 years of age) who provide written informed
consent will be included.
Exclusion criteria
Patients with chronic pancreatitis and patients with chronic
pain syndrome for any reason will not be admitted to the
PAKMAN trial because of possible pre-existing pain and
tolerance to pain medication. Moreover, patients with
severe chronic obstructive pulmonary disease (COPD,
stage ≥ III according to the Global Initiative for Chronic
Obstructive Lung Disease [GOLD] criteria) [11], or
American Society of Anesthesiologists (ASA) physical
status classification ≥ IV will be excluded. Furthermore,
the presence of contraindication(s) to the use of IV-
PCA or EDA (e.g., coagulopathies or allergies), partici-
pation in another intervention trial that interferes with
the intervention or outcome of this trial, impaired men-
tal state, or language problems will also prohibit inclu-
sion in the study.
Subject withdrawal criteria
Subjects may be withdrawn from the trial at their own
request or if a pancreatoduodenectomy is not performed
(e.g., because of technical irresectability or metastatic
disease). Withdrawn patients will be included in the final
report of the trial to ensure complete transparency.
Interventions
Pancreatoduodenectomy
The pancreatoduodenectomy may be performed as a clas-
sical, pylorus-preserving, or pylorus-resecting Whipple pro-
cedure. Furthermore, partial resection of the portal or
superior mesenteric vein is allowed. Pancreatic anastomosis
may be performed according to the local standard.
Description of trial interventions
All surgeons and anesthetists who participate in the
PAKMAN trial will receive instructions on which treat-
ment procedures are applicable to the two groups. Due
to the nature of a pragmatic trial with only a few exclu-
sion criteria and that focuses on effectiveness, no further
efforts are proposed to standardize the applied interven-
tions. In both groups, patients will receive intraoperative
general anesthesia according to local practice.
Intervention group A (IV-PCA)
For postoperative analgesia, intravenous opioids will be
used with the help of a patient-controlled-analgesia de-
vice according to local practice. The type of medication,
dosage, and additional pain medication will be docu-
mented in detail in the CRF.
Intervention group B (EDA)
Prior to induction with general anesthesia, a thoracic
epidural catheter will be inserted. This catheter will be
used intraoperatively and postoperatively according to
local standards in order to achieve anesthesia and anal-
gesia, respectively. Therefore, local anesthetics will be
injected with or without opioid analgesics into the epi-
dural space. EDA has to be used postoperatively for at
least 2 days. The type of medication, dosage, and add-
itional pain medication will be documented in detail in
the CRF.
Concomitant treatment
All additional medications and/or treatments will be
permitted during the trial when considered necessary
by the treating physicians. In the event of failed EDA
or premature cessation of the EDA, intravenous opioid
analgesia will be given as a rescue medication and doc-
umented. If epidural hematoma or neurological com-
plications occur, the standardized diagnostic and
treatment algorithm suggested by Pöpping et al. will
be used to assure patient safety [12]. The use of trans-
verse abdominal plane blocks, wound infusion catheters,
intrathecal medication, or perioperative IV infusion of
lidocaine will be prohibited.
Assignment of intervention and randomization
Consecutively screened and eligible patients will be in-
cluded in the trial at each center after initiation of the
study. To achieve comparable intervention groups for
known and unknown risk factors, patients will be allocated
in a concealed fashion by preoperative randomization
1 day before surgery using a centralized web-based tool
(randomizer.at) provided by the Institute of Medical In-
formatics, Statistics, and Documentation of the Medical
University of Graz, which has been successfully used in
previous trials. Stratification by center will be
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performed to minimize center effects. Therefore, selec-
tion bias (biased allocation to interventions) will be
minimized by sequence generation and allocation con-
cealment. Randomization will be conducted exclusively
by authorized trial personnel.
Primary and secondary endpoints
Primary endpoint
The primary endpoint, defined according to the retro-
spective trial by Pratt et al. that was used for sample-size
calculation [5], is the occurrence of at least one of the
following gastrointestinal complications on or before
POD 30:
– Delayed gastric emptying (grade A – C according
to the ISGPS (International Study Group of
Pancreatic Surgery) consensus definition) [13]
– Pancreatic fistula (grade A – C according to the
ISGPF (International Study Group of Pancreatic
Fistula) consensus definition) [14]
– Biliary leak (grade A – C according to the ISGLS
(International Study Group of Liver Surgery)
consensus definition) [15]
– Gastrointestinal bleeding (hematemesis,
hematochezia, or melena and no other source of
ongoing blood loss or the sudden appearance of
clinically evident blood either on nasogastric lavage
or per rectum, with a subsequent fall in hemoglobin
of 2 mg/dl and requiring blood product transfusion,
reoperation, or re-intervention (e.g., therapeutic
endoscopy or angiography))
– Postoperative ileus (absence of bowel sounds, failure
to pass flatus, or absence of bowel movement
by POD 5)
The composite primary endpoint “gastrointestinal com-
plications” will be assessed from the date of pancreatoduo-
denectomy up to the end of the study on POD 30.
Outcome observers will assess the presence of the pri-
mary endpoint during clinical visits and from the pa-
tients’ files and by a telephone call on POD 30. If at
least one item is assessed as present, the primary end-
point will have been reached for this patient. The sever-
ity of each complication will be classified by consensus
and according to the Clavien-Dindo classification [16].
If no consensus definition can be reached, the severity
will be assessed according to the Clavien-Dindo classifi-
cation only.
Key secondary endpoints
Secondary endpoints (Table 1) will be assessed by au-
thorized trial personnel during inpatient treatment and
by means of a telephone visit after discharge of the pa-
tient. Single items of the composite primary endpoint
will also be assessed as secondary endpoints. The
complete listing of secondary endpoints can be found
in Additional file 1.
Description of trial visits
During the screening visit (between 1 week and 1 day be-
fore operation), the inclusion and exclusion criteria will be
assessed. After the patient has given informed consent,
the demographic and baseline data, medical history,
current medication, comorbidities, prior imaging studies,
ASA class, Karnofsky Index, and Charlson Comorbidity
Index will be assessed and documented. Randomization
will be performed on the day before surgery by authorized
personnel only. On the day of surgery, visit 2 will be per-
formed, with assessment of intraoperative and periopera-
tive parameters as well as serious adverse events (SAEs).
Patients will be followed up for 30 days after pancreato-
duodenectomy, with follow-up visits scheduled on POD 2,
4, and 7 (POD 2 and 4 for pain and weight), and on day
14 or the day of discharge (whichever occurs first). During
the postoperative visits, the primary and secondary end-
points, final histopathology, and SAEs will be assessed and
documented. All planned study visits are summarized in
Table 2. Data from patients without partial pancreato-
duodenectomy (distal resection, total pancreatectomy,
enucleation, or exploration only) will be documented
up to the time of surgery (visit 2).
Safety aspects
As the two interventions compared in this trial are both
well-established and routinely used, only events fulfill-
ing at least one of the criteria for SAEs have to be re-
ported. SAEs occurring in the period from the day of
randomization to the end of follow-up have to be docu-
mented and reported to the coordinating investigator
within 5 days after they have become known. All on-
going SAEs (including SAEs in withdrawn subjects)
have to be followed up until no more signs and symp-
toms are verifiable or the patient is in a stable condi-
tion. Planned elective admission to the hospital and
planned elective surgery need not be reported because
these SAEs are assumed unrelated to the trial intervention.
Statistics
Hypotheses
The primary question is whether the rate of gastro-
intestinal complications is lower in one of the two
intervention groups. Let P1 be the rate of complications
in the IV-PCA group and P2 the rate of complications
in the EDA group. The null hypothesis (H0: P1 = P2, no
difference in the rate of gastrointestinal complications
between the two intervention groups) is tested against
the alternative hypothesis (H1: P1 ≠ P2, different rates of
gastrointestinal complications in the two groups).
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This two-sided problem is tested with a logistic regres-
sion model, which will include the covariates center, age,
body mass index, gender, and surgeon’s experience. Con-
firmatory analysis of the primary endpoint will be based
on the full analysis set (FAS), which is consistent with
the modified intention-to-treat (mITT) principle by the
inclusion of every patient who was randomized to one of
the study groups and received a pancreatoduodenect-
omy. This approach reflects the idea that the study re-
sults should match as closely as possible the conditions
in clinical practice.
Sample size calculation
The sample size calculation is based on the difference in
the frequency of gastrointestinal complications between
postoperative IV-PCA and thoracic EDA up to POD 30,
as it is very unlikely that any of the complications com-
bined in the primary endpoint will occur later than 30 days
after surgery. The prior assumption is based on the retro-
spective trial by Pratt et al. [5], who reported a 15 % differ-
ence (19 % versus 34 %) in the gastrointestinal
complication rate up to POD 30. Due to the possible im-
precision of the reported rates, a two-stage group
Table 1 Definition and assessment of key secondary endpoints
Secondary endpoint Definition Assessment
Pneumonia Presence of new infiltrate on chest x-ray OR
CT scan
Yes/no (severity according to Clavien-Dindo
classification)
Mortality Death before POD 30 during hospital stay as well
as after discharge
Yes/no, cause of death, and date of death
Hospital stay Days from day of initial operation to day of
hospital discharge
Days of inpatient treatment
Fluids given intraoperatively Amount of fluids given intraoperatively Crystalloid fluids in milliliters
Colloidal fluids in milliliters
Vasopressor therapy intraoperatively Amount of vasopressor during operation Type of vasopressor, amount in milligrams
Fluids given postoperatively Amount of fluids given postoperatively until POD
4 or death
Crystalloid fluids in milliliters, colloidal fluids
in milliliters
Vasopressor therapy postoperatively Amount of vasopressor after operation until POD
4 or death
Type of vasopressor, amount in milligrams
Weight over time/weight changes Patient’s weight on day of screening, POD 2, and
POD 4
Weight in kilograms
Re-operation Reoperation up to POD 30 or death Date and cause of every reoperation
Postoperative pain Pain level on POD 2 and 4 during movement
and at rest (NRS)
NRS
NRS numeric rating scale, POD postoperative day
Table 2 Planned investigation scheme
Visit V1 V2 V3 V4 V5 V6 V7
Before surgery
(days -7 to -1)
Day of surgery POD 2 POD 4 POD 7 POD 14 or day
of discharge
POD 30/EoS/premature
termination
Inpatient Telephone
Inclusion/exclusion criteria and
informed consent
X
Demographic and clinical baseline data X
Randomization Xa
Intervention X
Primary endpoint, assessment of
gastrointestinal complications
X X X X X
Secondary endpoints X X X X X X
Pain (NRS) X X
Weight X X
SAE X X X X X X
EoS end of study, V visit, POD postoperative day, SAE serious adverse event, NRS numeric rating scale
aRandomization 1 day before operation
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sequential design according to O’Brien and Fleming [17]
has been chosen, with the option of halting the trial for
reasons of either futility or efficacy after the primary end-
points of two-thirds of the total patients are known.. The
study will be stopped prematurely if the first-stage p-value
lies below 0.0146 or above 0.4. With a level of significance
a = 5 % and a power of 1-b = 80 %, a total sample size of
278 patients (139 per group) is sufficient when applying a
two-sided chi-square test (average sample size under H0,
201.6; under H1, 228.9; calculated with ADDPLAN6). To
account for the possibility that the observed difference
may be diminished by patient noncompliance and/or
dropout (assumed not to exceed 25 %), an additional 92
patients will be recruited to correct for these effects,
resulting in 370 patients (Figure 1).
Interim analysis
As soon as the primary endpoint has been assessed in
two-thirds (n = 185) of the total number of patients to
be randomized, an interim analysis will be performed. If
the study continues to the second stage, sample size
adaptation will be applied according to the inverse nor-
mal method [17], thereby controlling the overall two-
sided significance level of α = 0.05. Specific adaptation
scenarios were considered with simulations (100,000
replications each). These included adaptive doubling,
tripling, or quadrupling of the second-stage sample size
after the interim analysis. The results showed that suffi-
cient power would then be achieved, even if the relative
treatment effect of the intervention were overestimated
by 10 %, 15 %, or 18 %, respectively. However, when ad-
aptations are performed, the adaptive designs do not
apply sufficient test statistics and are less efficient than
the fixed designs planned for this effect [18]. The
amount of inefficiency was investigated and will be con-
sidered in the interim decision.
Premature closure of the trial
As described above, the trial will be stopped if the p-
value resulting from the planned interim analysis lies
Fig. 1 Planned investigation scheme
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below 0.0146 (for efficacy) or above 0.4 (for futility), to
ensure the statistical validity of the applied two-stage
group sequential design. It will also be stopped if the in-
terim analysis permits continuation of the study but the
recalculated sample size to achieve sufficient statistical
power is infeasible or inefficiently high.
Further analyses
An additional evaluation (sensitivity analysis) will be per-
formed with the per protocol set, and the results will be
compared with those of the ITT analysis. If a patient
leaves the trial prematurely without having experienced
an event with respect to the primary endpoint, the miss-
ing data for the primary outcome variable will be re-
placed using the ICA-r method described by Higgins et
al. [19]. Concerning secondary endpoints, exploratory
data analysis will be performed, with both appropriate
summary measures for the empirical distribution and
descriptive two-sided p-values being calculated. The
safety analysis includes the calculation and comparison
of frequencies and rates of serious SAEs. Furthermore,
statistical methods are used to assess the quality of data
and the homogeneity of the intervention groups. Details
of the statistical analysis will be fixed at the latest in the
statistical analysis plan to be prepared before database
lock and commencement of analysis. All analyses will be
conducted using SAS 9.1 or higher.
Data management
All protocol-required information collected during the
trial must be entered into the case report form (CRF) by
the investigator or a designated representative. The in-
vestigator or a designated representative must complete
the CRF as soon as possible after the information is col-
lected, preferably on the same day that a trial subject is
seen for an examination, treatment, or any other trial
procedure. Any outstanding entries must be completed
immediately after the final examination. An explanation
must be given for any missing data.
The completed CRF must be reviewed and signed by
the investigator or by a designated subinvestigator. A
copy will be retained at the trial center, and the original
CRF will be sent to the Institute of Medical Biometry
and Informatics Heidelberg (IMBI), which is in charge of
data management for the PAKMAN trial.
To ensure that the database reproduces the CRFs cor-
rectly, the IMBI will perform the data entry twice. IMBI
representatives will check completeness, validity, and
plausibility of all data using validation programs, which
will generate queries. All validation rules will be prede-
fined in a data-validation plan. The investigator, or a
designated representative, will be obliged to resolve the
queries. As soon as no further corrections or clarifica-
tions are required, the database will be closed and used
for statistical analysis. The data will be managed and
analyzed according to the appropriate standard operat-
ing procedures of the IMBI.
Data monitoring
Monitoring will be conducted according to approved stand-
ard operating procedures, which include personal onsite
visits with source data verification. Clinical monitoring
within the PAKMAN trial will be performed according to
the ICH-GCP guideline (E6) by the Coordination Centre
for Clinical Trials (KKS) Heidelberg. Monitoring proce-
dures will be predefined in a study-specific monitoring
manual. Monitoring details will be adapted to the study-
specific risks for the patients.
Ethical and legal aspects
The responsible investigator will ensure that the PAK-
MAN trial adheres to the tenets of the Declaration of
Helsinki in its current version and to the laws and reg-
ulations of the country concerned. This protocol is de-
signed to ensure that the trial will be conducted and
analyzed in accordance with ICH E6 Good Clinical
Practice [20]. The protocol has already been approved
by the independent ethics committee (IEC) of the med-
ical faculty of the University of Heidelberg, and second-
ary approval of the corresponding ethical bodies of all
other participating centers has been or will be obtained.
Additional file 2 contains a list of all local ethical bodies
that have approved the PAKMAN trial. Recruitment in
any center will not start before its individual ethical ap-
proval has been obtained. Any amendments will be
signed by all parties and submitted to all of the IEC,
and the IEC will also be informed at the end of the trial.
The trial protocol has been formulated in accordance
with the recommendations of the CONSORT and
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines (Additional file 2)
[21, 22].
Discussion
Previous research comparing IV-PCA and EDA has fo-
cused mainly on the level of pain control itself [4, 23] or
on the incidence of cardiac and pulmonary complica-
tions [4, 6]. The reported mean visual analog pain scores
are 3.2 ± 1.6 with IV-PCA versus 2.1 ± 1.3 with EDA.
This difference is statistically significant but of minor
clinical relevance at best and diminishes during the post-
operative course [4, 23]. In addition, up to 30 % of the
patients with EDA still experience severe pain in clinical
practice [24]. In contrast to the subjective belief of many
anesthetists, the failure of epidural anesthesia and anal-
gesia is a frequent clinical problem (failure rate 13 % to
47 % in experienced hands) [23, 25].
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The postulated benefits of EDA are reduced consump-
tion of anesthetics, improved pain control with higher
patient satisfaction, reduced incidence of cardiac and
pulmonary complications, reduction of the surgical
stress response, early bowel recovery, and enhanced
postoperative recovery with shorter hospital stay [4, 6].
Despite these postulated benefits, the influence of EDA
on clinically relevant outcomes is not clear [26]. Al-
though conclusions from historical studies have been
promising, recent studies have shown no relevant effect
[23]. Only weak evidence exists that EDA is able to de-
crease postoperative cardiovascular and pulmonary
complications for subgroups with major open vascular
surgery or high-risk patients [23, 27]. A 2011 meta-
analysis investigating the effects of thoracic EDA on
perioperative outcome failed to show a benefit on peri-
operative in-hospital mortality in noncardiac surgery
[7]. In a single-center RCT, the preemptive use of EDA
in patients undergoing open colon resection offered no
advantage over IV-PCA with regard to the length of the
hospital stay, pain scores, quality of life, complications,
or hospital costs [28]. Even in high-risk patients under-
going major abdominal surgery, most adverse outcomes
are not reduced by the use of EDA [29].
Furthermore, the risk of epidural hematoma and para-
plegia after EDA seems to be higher than previously as-
sumed [12]. The German network for safety in regional
anesthesia reported the incidence of epidural hematoma
after EDA as 1:6,628 [30].
Pain control and the incidence of cardiac or pulmon-
ary complications are critical to patients but form only
a minor part of patient-relevant outcome parameters
after major surgical operations such as pancreatoduo-
denectomy. Most trials to date have not correlated
analgesic treatment with surgical complications. Our
primary endpoint is of high clinical relevance for pa-
tients undergoing pancreatoduodenectomy because
nearly every single gastrointestinal complication easily
meets the definition of an SAE, and the high morbidity
is mainly caused by these very complications. The val-
idity and reproducibility of our results will be secured
by a clear-cut definition of all outcome parameters and
the use of international consensus definitions, when
available.
The sample size calculation is based on a single retro-
spective study [5], and possibly, the rates reported there
are imprecise. For this reason, a two-stage group se-
quential design is planned, with the option of stopping
both for futility and for efficacy after the primary end-
point is reached in two-thirds of the total patients. In
the case of continuation of the trial, the sample size will
be adjusted. Furthermore, to account for possible non-
compliance and dropout of patients, 25 % more partici-
pants will be recruited than are needed.
The PAKMAN trial is designed as a pragmatic trial
because the objective is to depict the effectiveness of
interventions in real-life routine practice conditions
and produce results that can be generalized. The
broad inclusion and narrow exclusion criteria reflect
the pragmatic nature of the trial and the aim to obtain
results with high generalizability and high external
validity. Therefore, a number of interference factors,
such as the experience of the surgeon (in terms of
number of pancreatoduodenectomies performed (< 26,
26-50, 51-75, or > 75)), the underlying disease (benign
versus malignant), the method of pancreatic anastomosis
(pancreatogastrostomy versus pancreatojejunostomy), and
the type of general anesthesia (medication, dosage, and
type of application) will be assessed and available for
subgroup analysis. These factors, however, were not
predetermined in the study protocol. Moreover, by ran-
domizing 370 patients, the known and unknown con-
founders will be distributed equally.
The risk of performance bias due to nonblinding is low
because objective endpoints are used. Blinding of the pa-
tients and treating physicians is not possible as a matter of
principle. The impact of a blinded observer on the reduc-
tion of bias would only be marginal because the primary
endpoint (delayed gastric emptying, pancreatic fistula, bil-
iary leak, gastrointestinal bleeding, or postoperative ileus)
is defined in detail and already well documented (e.g., op-
eration or intervention reports) in daily practice. It seems
unlikely that these objective trial results will differ signifi-
cantly if the observer is unblinded [31].
The difference on which the PAKMAN trial focuses is a
qualitative one (induced sympathicolysis due to any kind
of EDA against IV-PCA without sympathicolysis). There-
fore, only particular key steps of the interventions are pre-
defined, and procedures can otherwise be performed
according to local practice. EDA and IV-PCA medication,
dose, and mode of application will be documented but not
standardized. EDA and IV-PCA will be performed accord-
ing to the centers’ standard procedures. Nevertheless, the
detailed documentation will allow additional subgroup
analysis regarding type/dose of medication for EDA or IV-
PCA and frequency of gastrointestinal complications.
The results of the PAKMAN trial could influence fu-
ture guidelines and decision-making. Healthcare costs
might be decreased by a reduction of the complications
themselves and of the treatment and hospital stay re-
quired to deal with the complications. Furthermore, any
other treatment needed by patients (e.g., chemotherapy)
might be delayed less often by complications.
Trial status
Recruitment of patients for the PAKMAN trial started in
June 2015 (the first patient was randomized on 30 June
2015), and the trial is expected to be complete in 2017.
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